# BlinkBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blinkbio

- Industry: Biotechnology
- Headquarters: Jupiter, US
- Website: www.blinkbioinc.com
- Total disclosed funding: $5.5M
- Latest round: Series B (Jun 28, 2012)
- Investors on record: 4

## About

BlinkBio, Inc. is a biotechnology company dedicated to developing advanced genomic medicines for complex medical conditions, focusing on oncology and rare genetic disorders using innovative technologies.BlinkBio, Inc. was founded in 2009 and is headquartered in Jupiter, US. The company specializes in biotherapeutic solutions and has engaged in 9 deals as an investment target. The most recent deal occurred on May 7, 2019, when BlinkBio raised USD 0.53 mn in a VENTURE DEBT round led by Noble Capital Markets. The total amount raised by the company to date amounts to USD 10.86 mn. The CEO of BlinkBio is Colin Goddard.Blink Bio Inc. specializes in advanced biotherapeutic solutions that leverage innovative technologies to address complex medical conditions. Their core offerings include next-generation genomic medicines designed to target specific diseases, particularly in oncology and rare genetic disorders. These products employ techniques such as gene editing and targeted delivery systems to enhance therapeutic efficacy and minimize off-target effects. The target clientele includes healthcare providers, research institutions, and pharmaceutical companies, primarily serving markets in North America, Europe, and select regions in Asia.The revenue model for Blink Bio Inc. revolves around strategic partnerships with healthcare entities and direct sales of proprietary biotherapeutics. Transactions typically occur through B2B agreements with hospitals, specialty pharmacies, and research organizations, facilitating the distribution of their flagship products. The company implements a subscription-based pricing plan for certain services, allowing clients to access ongoing support and updates on product innovations. Pricing structures for individual products or services are established based on the complexity and uniqueness of the therapies offered.BlinkBio plans to leverage its recent funding of USD 0.53 mn from May 2019 to support the development of new genomic medicines targeting additional rare genetic disorders. The company aims to expand its reach into new markets across Europe and Asia by 2025, enhancing its presence in regions with a growing demand for biotherapeutic solutions.

## Funding rounds

- Series B, Jun 28, 2012, $5.5M — Hatteras Venture Partners, Ascent Biomedical Ventures, MedImmune Ventures, Argent Ventures

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series B
- Ascent Biomedical Ventures (https://capitalatlas.ai/funds/ascent-biomedical-ventures) — Series B
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series B
- Argent Ventures — Series B